|
Therapeutic Use of Obeticholic Acid for the Mitigation of Non-Alcoholic-Fatty Liver Disease: A Systematic Review
|
|
| Author:
|
HAWKAR A ABDALLA, DR M SUMITHRA, DR V CHITRA
|
| Abstract:
|
Non-alcoholic-fatty liver disease (NAFLD) is the most prevalent disease currently affecting the population
worldwide. NAFLD is mainly characterized by an overall intensification in the intrahepatic triglyceride level
content. NAFLD is an multicentric disease and is linked with liver damage associated with several disease like
obesity, insulin resistance and many others. Due to the limitations on biopsy of the liver, the prevalence of the
disease is unclear yet and much work is still yet to be established both in epidemiological studies and potential
biomarkers. The trademark feature of NAFLD is steatosis. In normal incidences the published prevalence of
hepatocellular carcinoma (HCC) is considerably low in NAFLD/NASH patients. Using predefined inclusion
criteria, all RCTs included in this review were that obeticholic acid is compared with placebo or either only
assessment of safety and efficacy of Obeticholic Acid in patients with NAFLD are included in this review. Data
shows Obeticholic acid exhibits a significant improvement in treatment groups when compared with placebo
groups. We observed that therapy of obeticholic acid had an advantageous effect on patients suffering with
NAFLD. However, OCA was generally well tolerated but there are major adverse drug reactions. pruritus and
few studies reported that diarrhoea and constipation were also observed as minor ADR. The overall out come
that we can conclude is that Obeticholic acid therapy had a beneficial effect on patients with NAFLD.
|
| Keyword:
|
Obeticholic acid, Fatty liver, Non-alcoholic, Pruritis, cirrhosis.
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2021.13.02.264
|
| Download:
|
Request For Article
|
|
|